Menu

Martha Brumfield on the Success and Continued Growth of CPTR

How CPTR has grown into a vital and innovative catalyst in the fight against TB

Perspectives

thumb-fauci

US NIAID’s Anthony Fauci on Halting Drug Resistance

New TB drug regimens and diagnostics are needed to fight TB and MDR-TB

thumb-eichler

EMA’s Hans-Georg Eichler on Innovation Within Regulation

Instead of gatekeepers, regulators must act as enablers of innovation

thumb-mayowa

Advocate Mayowa Joel on Community Engagement

Effective and sustainable community engagement programs is a critical priority

News

World TB Day 2015 Supplement Profiles TB Diagnostic Landscape

Read the supplement to the Journal of Infectious Diseases called “Tuberculosis Diagnostics in 2015: Landscape, Priorities, Needs, and Prospects,” which can be found here. Madhukar Pai and Marco Schito write: “In 2015, tuberculosis remains a major global health problem, and drug-resistant tuberculosis is a growing threat. Although tuberculosis diagnosis in many countries is still reliant on older tools, […]

March 20, 2015 Drug Development RDST

Regulatory Authorities Support First Drug Development Tool, Critical to Advance TB R&D Efforts

The first nonclinical drug development tools (DDTs), developed by working groups within CPTR, have been endorsed by leading global regulatory authorities. DDTs with demonstrated predictive accuracy for clinical and microbial outcomes are needed to support effective regimen development decision-making. Endorsement of these DDTs by regulatory authorities is critical for drug developers as it promotes confidence in […]

March 19, 2015 Drug Development Regulatory Science clinical trials hollow fiber model

From the Working Groups

Clinical Trials Infrastructure Workgroup Q1 2015 Update

The Clinical Trials Infrastructure Workgroup (CTI-WG) identifies efficiencies across clinical trial sites and supports a coordinated approach to clinical research for TB regimen development. Progress over the first quarter of 2015 can be read here.

March 16, 2015

Global Regulatory Pathways Workgroup Q1-2015 Update

The Global Regulatory Pathways Workgroup (GRP-WG) identifies efficiencies in the regulatory pathway to develop a novel regimen by fostering dialogue among key regulatory agencies, WHO, and NTPs. The Workgroup works to develop of pathway for regulatory approval that incentivizes regimens development. Regulators from countries or regions with high TB burden are included in this process.

March 16, 2015

Stakeholder & Community Engagement Workgroup Q1-2015 Update

The Stakeholder and Community Engagement Workgroup (SCE-WG) facilitates the development of regimens by early, effective, and appropriate collaboration of key stakeholders and by building awareness and support among communities. The ability to successfully engage the community while conducting clinical trials is an essential component for regimen development.

March 16, 2015
About CPTR

Through partnership, CPTR speeds the development of new and markedly improved drug regimens for tuberculosis.